Med-Fine Capital
VC Fund
Shanghai, China
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
- Total investments:
- 83
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $73M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Med-Fine Capital invests in
Stages Med-Fine Capital invests in
Countries Med-Fine Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $8M–$60M
- Series A
- $3M–$40M
- Series B
- $12M–$60M
Investment Focus
Industry
- Medical 30 (36%)
- Health Care 29 (35%)
- Biotechnology 24 (29%)
- Medical Device 10 (12%)
- Biopharma 9 (11%)
Stage
- Series A 28 (34%)
- Seed 20 (24%)
- Series B 12 (14%)
- Series C 7 (8%)
- Angel 4 (5%)
Country
- China 57 (69%)
- Hong Kong 1 (1%)
- United States 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Hu Hongdan
executive director
|
executive director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing. | $21.8M / Series C / Apr 03, 2026 | ||
|
Zhuanma Biotech
|
Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all." | Seed / Mar 24, 2026 | |
|
Tianyikang Biotechnology
|
Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products. | Seed / Feb 09, 2026 | |
| BV Laser is a manufacturer of medical beauty equipment. | $14.2M / Series C / Dec 15, 2025 | ||
| Phrontline Biopharma specializes in the development of ADC to address unmet medical needs in the field of oncology. | $60M / Seed / Nov 21, 2025 | ||
|
Excalipoint Therapetics
|
Excalipoint Therapeutics is a Private limited company. | Series A / Aug 04, 2025 | |
|
Excalipoint Therapetics
|
Excalipoint Therapeutics is a Private limited company. | $41M / Seed / Aug 04, 2025 | |
| Allink Biotherapeutics is a biopharmaceutical company that focuses on oncology and immunological treatment. | $42M / Series A / Nov 28, 2024 | ||
| BV Laser is a manufacturer of medical beauty equipment. | Series B / Nov 25, 2024 | ||
| ZD Medical develops phase variance optical coherence tomography that can detect macular degeneration and retinal microvascular proliferation caused by diabetes at the same time. It is a non-invasive, early-detection technology for diabetic retinopathy. ZD Medical's phase variance optical coherence tomography can detect both maculardegeneration and retinal microvascular proliferation caused by diabetes. ZD Medical brings together scientific and technological elites from both at home and abroad to pursue the development and manufacture of high-quality medical devices, and is dedicated to providing practical overall solutions for medical diagnosis and clinical treatment in order to benefit humanity's medical and health causes. | $14M / Series C / Nov 01, 2024 | ||
| See all 83 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Med-Fine Capital invest in?
Med-Fine Capital invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Seed stage. Most of the 83 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Med-Fine Capital's check size?
Med-Fine Capital typically joins rounds of $8M–$60M at Seed, $3M–$40M at Series A and $12M–$60M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Med-Fine Capital participates in.
How do I contact Med-Fine Capital?
Public channels for Med-Fine Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Med-Fine Capital?
The team at Med-Fine Capital includes Hu Hongdan (executive director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
